Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( <scp>SUSTAIN</scp> 11): A randomized, open‐label, multinational, phase 3b trial-Reference-Cited by-同舟云学术

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes ( SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Published:2022-06-29 Issue:9 Volume:24 Page:1788-1799
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Kellerer Monika¹^ORCID,Kaltoft Margit Staum²,Lawson Jack²,Nielsen Lasse Lykke²,Strojek Krzysztof³,Tabak Ömür⁴,Jacob Stephan⁵^ORCID

Affiliation:

1. Centre for Internal Medicine I Marienhospital Stuttgart Germany

2. Novo Nordisk A/S Søborg Denmark

3. Department of Internal Diseases Diabetology and Cardiometabolic Diseases, Faculty of Medical Sciences in Zabrze Medical University of Silesia Katowice Poland

4. Istanbul Kanuni Sultan Suleyman Education and Research Hospital Istanbul Turkey

5. Department of Internal Medicine, Division of Endocrinology/Diabetology Cardiometabolic Institute Villingen‐Schwenningen Germany

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14765

Reference44 articles.

1. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes